|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.86 CHF | -0.44% |
|
-8.53% | +96.56% |
| Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
| Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Kuros Biosciences AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was CHF 33.56 million compared to CHF 17.99 million a year ago. Net loss was CHF 13.73 million compared to CHF 14.6 million a year ago.
Basic loss per share from continuing operations was CHF 0.38 compared to CHF 0.43 a year ago. Diluted loss per share from continuing operations was CHF 0.38 compared to CHF 0.43 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +96.56% | 276M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
KUROS BIOSCIENCES AG 
